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Abstract
Background: To identify prognostic factors in patients with parotid gland carcinomas who were treated at the
Princess Margaret Hospital.
Methods: Clinical outcome of two hundred fifteen patients with malignancies of the parotid gland was evaluated
over a 16-year period.
Results: Two-hundred-fifteen patients with adenoid cystic carcinoma (n = 20), adenocarcinoma (n = 19), acinic cell
carcinoma (n = 62), basal cell adenocarcinoma (n = 7), carcinoma-ex-pleomorphic adenoma (n = 18), mucoepidermoid
carcinoma (n = 70) and salivary duct carcinoma (n = 19) have been included. The 5- and 10-year overall and
disease-free survivals were 80.62 %/69.48 % and 74.37 %/62.42 %, respectively. Multivariable analysis showed that age
greater than 60 years, advanced pN classification, histopathological grade and the presence of lymphovascular invasion
significantly worsened overall and disease-free survival. Univariable analysis revealed periparotid lymph node
involvement was associated with decreased overall (p < 0.0001) and disease-free survival (p < 0.0001).
Conclusions: In addition to age, pN classification, histopathological grade, perineural invasion, and lymphovascular
involvement, periparotid lymph node metastasis appears to be an important prognosticator in parotid gland
malignancy.
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Introduction
Malignant salivary glands tumors are rare, representing
only 2 % of all head and neck malignancies [1]. Salivary
gland carcinomas represent a heterogeneous group of
malignancies with diverse biological behaviors [2, 3],
rendering standardization of management extremely dif-
ficult. In the first large published case series of 2807 pa-
tients with salivary gland malignancies over a 35 year
period, Spiro [3] reported that the site of origin, histo-
logic subtype, grading, and clinical stage were significant
prognostic factors for overall survival. Wahlberg et al.
[4] analyzed a Swedish cohort of 2465 patients treated
between 1960 and 1998 for malignant parotid tumors
and found that histopathological subtype, age and sex
were also significant clinical predictors for survival [4].
Other studies have demonstrated the importance of
regional lymph node involvement, positive surgical
margins, perineural invasion, and facial nerve palsy as
significant clinical predictors of outcome [4–7]. Recent
studies have investigated molecular prognosticators asso-
ciated with less favorable outcomes in those with salivary
gland malignancy [8–11]. Interpretation of the literature is
often difficult as patients in a given case series have typic-
ally been treated over extended periods of time, and using
non-uniform treatment modalities [12].
The primary objective of this study was to analyze the
outcome and patterns of failure in 215 patients with ma-
lignant parotid gland tumors managed at the Princess
Margaret Cancer Centre (Toronto, Canada). The sec-
ondary objective was to evaluate whether previously
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reported clinical and pathologic factors were significant
predictors of survival.
Material and patients
A retrospective review of 215 consecutive patients with
primary parotid gland cancers treated at the Princess
Margaret Cancer Center between 1989 and 2005 was
performed. Patients were identified through the Princess
Margaret Cancer Registry and cross-referenced with a
head and neck surgical registry. Approval was obtained
from the Institutional Research Ethics Board prior to
data collection. Patients with a newly diagnosed malig-
nancy arising within the parotid were included in the
study if they received some or all of their treatment at
the Princess Margaret. A subset of patients included
were those that had their initial surgery at an outside in-
stitution that were referred in shortly after their initial
procedure for either further resection followed by radi-
ation or for post-operative radiation alone. Patients with
submandibular, sublingual and minor salivary gland can-
cers, lymphomas or malignancies metastatic to the saliv-
ary glands were excluded. Patients were also excluded if
they were treated with palliative intent.
The management approach at the Princess Margaret
for patients with parotid gland malignancy has been sur-
gical resection with adjuvant radiotherapy used in those
patients with positive margins, high-grade histology,
perineural invasion/spread or nodal metastases, or where
uncertainty existed about completeness of resection,
usually arising from very close juxtaposition of the
tumor to the facial nerve. Generally, in cases where the
tumor was abutting but not invading the facial nerve
and nerve function was normal pre-operatively, the facial
nerve was preserved with the addition of post-operative
radiotherapy. Therapeutic neck dissections were per-
formed when there was clinical or radiographic evidence
of nodal metastases. In patients without any evidence of
nodal metastases, prophylactic neck dissection was per-
formed in those patients with high-grade malignancies.
For all patients undergoing surgery, the surrounding
lymph nodes were examined, including the upper neck
in parotid tumors. Enlarged nodes were sampled and if
frozen section examination confirmed metastases, an ap-
propriate neck dissection was performed. Patients that
had an initial surgery at an outside center were offered
revision surgery prior to post-operative radiotherapy if
they had residual disease on MRI, otherwise they were
managed with post-operative radiotherapy alone.
Diagnosis of all tumors was performed by head and
neck pathologists and classified according to the World
Health Organization (WHO) classification of salivary
gland malignancies [2]. Demographic, clinical, and
pathological data was obtained from hospital records.
The pathological parameters included histologic subtype,
perineural invasion (PNI), lymphovascular invasion
(LVI), margin status, extra capsular extension and me-
tastases to the peri-parotid lymph nodes. Peri-parotid
and intra-parotid lymph nodes were defined as those
nodes attached to or within the parotid gland, respect-
ively. The grade of the tumour when reported by the
pathologist was recorded. Disease was staged at the time
of initial presentation using the American Joint Commit-
tee on Cancer (AJCC) classification staging system.
Statistical analysis
Descriptive statistics were used for describing patient
demographics and pathological characteristics. Categor-
ical variables were expressed as counts and proportions,
whereas continuous variables were expressed as means
with standard deviations (SD). Outcome measures in-
cluded control rates, overall survival (OS) and disease-
free survival (DFS), which were estimated using the
Kaplan-Meier product method. Time to event outcomes
were calculated from the date of diagnosis to the event
of interest. Differences between survival curves were an-
alyzed using the log-rank test.
Potential prognostic variables achieving significance
level of 0.20 or less on univariable analysis were subse-
quently entered into a multivariable Cox-proportional
hazards model and stepwise model-building was used to
determine the simplest model that best described the as-
sociation in the data. Histologic subtype was not incor-
porated into the multivariable analysis for either OS or
DFS as this would lead to excessive stratification of the
data given the number of patients in the study. Grade
was included in the multivariable analysis; however,
since the majority of patients were either low or high
grade, the intermediate grade patients were grouped
with the high-grade patients. All p-values were 2-sided.
Results were considered significant if p < 0.05. Statistical
analyses were performed using SAS (Version 9.3, SAS
Institute, Inc., Cary, NC).
Results
A total of 215 patients with parotid gland cancers man-
aged with primary surgery were included in the study.
The mean (median) age of the patients was 55 (56) years
(range 15–91) and 112 patients (52 %) were female. Out
of the 215 patients only 12 (5.6 %) patients presented
with a facial paralysis.
Facial nerve preserving surgery was performed in 179
patients with 28 patients undergoing a total parotidect-
omy with nerve sacrifice and an additional 8 had a total
parotidectomy, nerve sacrifice and temporal bone resec-
tion. Adjuvant post-operative radiotherapy was given to
168 (78 %) patients. The mean and median radiation
dose was 58 and 60 Gy, respectively (range from 35 to
70Gy). Neck dissections were performed in 105 (48.8 %)
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patients. Selective and modified radical neck dissection
was performed in 81 (37.7 %) and 19 (8.8 %) patients, re-
spectively. An additional 90 patients that did not have
planned neck dissection had pathologic assessment of
the intraparotid or periparotid lymph nodes.
Tumor characteristics, including T and N classifica-
tion, are summarized in Table 1. Mucoepidermoid car-
cinoma (MEC) was the most common histologic variant
of parotid gland cancer, accounting for 32.5 % percent of
cases, followed in frequency by acinic cell (28.8 %) and
adenoid cystic carcinoma (ACC) (9.3 %). Histopatho-
logical grade for each histologic subtype of parotid can-
cer, if specified is presented in Table 2.
Positive surgical margins (i.e. tumor extending to the
inked margin of specimen) were identified in 38.9 % (n =
77/198) of patients who underwent parotidectomy. Mar-
gin status was not available for 17 patients. Positive mar-
gins were reported in 12 patients with ACC, 10 patients
with salivary duct carcinoma, and 6 patients with carcin-
oma ex-pleomorphic adenoma. Positive margins were
noted in 34.8 % of patients (31/89) with grade 1 tumors,
32.3 % of patients (10/31) with grade II tumors, and
45.1 % of patients (32/71) with grade III tumors. Of the
patients with positive margins, 36 (46.8 %) had their initial
surgery performed at an outside center and were re-
ferred for further management. Eight of these patients
underwent a repeat surgical resection as part of their
management.
Perineural invasion (PNI) was reported in 53 (26.9 %)
patients. Salivary duct carcinoma had the highest fre-
quency (72.2 %, n = 13/18), followed by ACC (45 %, 9/
20), adenocarcinoma (52.6 %, 10/19), carcinoma ex-
pleomorphic adenoma (21.4 %, 3/14), MEC (16.4 %,
10/61), and acinic cell carcinoma (8.3 %, 5/58). The in-
cidence of perineural invasion increased with histo-
pathological grade. PNI was reported in 4.4 % (4/90) of
grade I tumors, 26.7 % (8/30) of grade II tumors, and
55.7 % (39/70) of grade III tumors (p-value < 0.0001).
Lymphovascular invasion (LVI) was reported in 40
(20.6 %) patients. It occurred most commonly in saliv-
ary duct carcinomas (61.1 %, n = 11/18), followed by
adenocarcinoma (52.6 %, 10/19), carcinoma ex-
pleomorphic adenoma (42.9 %, 6/14), acinic cell carcin-
oma (14.0 %, 8/57), ACC (10.5 %, 2/19), and MEC
(5 %, 3/60). LVI was uncommon in grade I and grade II
tumors (7.9 % and 6.7 %, respectively); however, it was
frequently found in grade III tumors 31/40 (45.6 %) (p-
value <0.0001).
Overall, 52 patients had nodal metastases. Thirty-five
(67.3 %) of these patients had positive periparotid lymph
nodes noted on final pathology, 29 (82.9 %) of which
had extranodal extension. Periparotid nodal metastases
were most commonly noted with salivary duct carcin-
omas (61 %; 11/18). This was followed in frequency by
adenocarcinoma (22.7 %; 5/22), MEC (17.9 %; 12/67),
acinic cell carcinoma (8.2 %; 5/61), carcinoma ex-
pleomorphic adenoma (6.7 %; 1/15), and ACC (3.9 %; 1/
26) (p-value < 0.0001). The incidence of periparotid
nodal metastases increased with histological grade; 7.5 %
of grade I tumors demonstrated periparotid nodal me-
tastases, 11.8 % of grade II tumors, and 30 % of grade III
tumors (p-value = 0.0003). Among the 35 patients with
positive periparotid nodes 17 (56.7 %) were staged clinic-
ally as N0 (clinical nodal staging was not available for 5
patients). Moreover, of the 35 patients, with a positive
periparotid node 38.8 % also had lateral neck nodal me-
tastases, in contrast to 2.7 % of patients with negative
periparotid nodes.
Outcome
The mean and median follow-up durations for the entire
cohort were 85.2 and 80.7 months, respectively. The
mean and median follow-up durations of living patients
were 101 and 102 months, respectively. At the time of
last follow-up, 148 (68.8 %) patients were alive without
disease, 7 (3.3 %) were alive with disease, and 4 (1.9 %)
were lost to follow up (patients alive at last visit but with
less than 2 months of follow-up). During the observation
period, 36 patients (16.7 %) died of disease and 6 (2.8 %)
died of other causes. The mean time to death was
39.9 months (range 1.77-129.64 months).
Recurrence
During the study period 48 patients (22.3 %) developed a
recurrence. Twelve developed local recurrence, 7 devel-
oped regional recurrence and 29 developed distant me-
tastases. Eleven of these patients had two sites of
recurrence, with the most frequent combination (n = 9,
4.2 %) being local and distant failure. The recurrence
rate for node positive and node negative patients was
63.5 % and 23.0 %, respectively (p < 0.0001). The odds
ratio of developing recurrent disease in the node positive
compared to the node negative group was 5.80 (95 % CI
2.88-11.70). Furthermore, the incidence of distant metas-
tases was significantly higher in the node positive group
(30.8 %) than for the node negative group (6.35 %; p-
value <0.0001). The odds ratio of detecting distant meta-
static disease in the node positive group was 6.55 (95 %
CI 2.59-18.56) compared to the node negative group. Pa-
tients with lymphovascular invasion had a significantly
higher chance of having distant metastases (72.2 %)
compared to those without lymphovascular invasion
(39.1 %, p = 0.023).
Survival
For the entire cohort, the mean and median follow-up
time was 85 and 81 months (range 1–256 months), re-
spectively. The 5- and 10-year OS was 80.6 % and
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69.5 %, respectively. The 5- and 10-year DFS was 74.4 %
and 62.4 %, respectively.
Histological subtype was a clear predictor of OS (Fig. 1)
on univariable analysis. Other predictors of OS are summa-
rized in Table 3. Significant predictors of OS on multivari-
able analysis are summarized in Table 4. Lymphovascular
invasion, histopathologic grade, nodal status, age >60 and
adjuvant radiation therapy was shown to be a significant
predictor for overall survival. Patients who received radio-
therapy postoperatively had a significant prolonged overall
survival compared to patients who had no adjuvant radio-
therapy (p = 0.007).
Predictors of disease-free survival (DFS) on univariable
analysis are summarized in Table 3. Margin status was
not a significant predictor of outcomes on UVA for either
OS or DFS. Predictors of DFS on multivariable analysis
were lymphovascular invasion, pathologic N classification,
perineural invasion and age > 60 years (Table 5). Fig. 2
presents the Kaplan Meier DFS curves for the histologic
subtype (p < 0.0001).
Discussion
The heterogeneous nature of parotid gland malignancies,
along with their diverse biological behavior and relative
rarity can make their management very challenging.
Knowledge of clinical and histopathologic prognostic
factors is critical to making appropriate decisions regard-
ing therapeutic options [4, 12, 13]. We sought to per-
form a review of outcomes of parotid cancer outcomes
managed at a single tertiary care oncology center in the
modern era and assess for predictors of outcome.
Our study cohort was comparable in demographic and
clinicopathologic data to other recently published reports
Table 1 Demographic and clinicopathological data of 215
patients with major salivary gland carcinoma
Variable Number of patients (%)
Total = 215
Morphology Acinic carcinoma 62 (28.84 %)


















T1 68 (34.17 %)
T2 61 (30.65 %)
T3 48 (24.12 %)
T4a 20 (10.05 %)
T4b 2 (1.01 %)
na 16 (7.44 %)
Pathological Lymph
node status
N0 126 (70.79 %)
N+ 52 (29.21 %)
na 37 (17.2 %)
Pathological Staging I 64 (33.51 %)
II 46 (24.08 %)
III 40 (20.94 %)
IVa 41 (21.47 %)
na 24 (11.16 %)
Pathological Grading I 94 (45.41 %)
II 34 (16.43 %)
III 79 (38.16 %)
na 8 (3.72 %)
Margin status negative 121 (61.11 %)
positive 77 (38.89 %)
na 17 (7.90 %)
Perineural invasion negative 144 (73.10 %)
positive 53 (26.90 %)
na 18 (8.37 %)
Lymphovascular
invasion
negative 154 (79.38 %)
positive 40 (20.62 %)
na 21 (9.76 %)
Extracapsular extension negative 169 (88.48 %)
positive 22 (11.52 %)
na 24 (11.16 %)
Table 1 Demographic and clinicopathological data of 215
patients with major salivary gland carcinoma (Continued)
Periparotid lymph node
involvement
negative 167 (82.67 %)
positive 35 (17.33 %)
na 13 (6.04 %)
na = not available
Table 2 Histopathological grading for each histologic subtype
of parotid cancer
Histology Grade I (%) Grade II (%) Grade III (%)
Acinic Cell Carcinoma 53 (87) 2 (3) 6 (10)
Adenocarcinoma NOS 1 (5) 3 (16) 15 (79)
Adenoid Cystic Carcinoma 6 (35) 4 (24) 7 (41)
Basal Cell Adenocarcinoma 4 (80) 0 1 (20)
Carcinoma-ex Pleomorphic
Adenoma
4 (22) 1 (6) 13 (72)
Mucoepidermoid carcinoma 26 (38) 24 (35) 18 (26)
Salivary duct Carcinoma 0 0 19 (100)
Erovic et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:43 Page 4 of 8
[7, 14]. Mucoepidermoid carcinoma and acinic cell car-
cinoma were the two most common variants. Patients
with acinic cell, adenoid cystic and mucoepidermoid car-
cinoma had a better overall and recurrence-free survival
compared to patients diagnosed with salivary duct carcin-
oma, carcinoma-ex-pleomorphic adenoma and adenocar-
cinoma. As has been demonstrated by the data in this
study and others, patients can be stratified to high or low
risk for survival according to their histology, as well as to
their grade.
In concert with prior studies, we have also observed
that patients with positive neck nodes, perineural, and
lymphovascular invasion have lower overall and disease
free-survival [7, 15, 16]. Similar to previous reports, pa-
tients younger than 60 years have a better disease-free
survival than older patients. The explanation for this
finding is unclear, although immunologic or other age-
associated factors may play a role [17, 18].
Controversy exists as to the most appropriate manage-
ment of the neck in patients with primary malignancies
of the parotid. One of the complicating factors is the fre-
quent lack of a preoperative histological subtype diagno-
sis. While most head and neck oncologists agree that
elective neck dissection is warranted in those undergo-
ing parotidectomy for high-risk or high-grade disease,
stratification is often unknown at the time of primary
surgery. Furthermore, in the setting of known malig-
nancy, clinical nodal evaluation appears to significantly
underestimate the true incidence of cervical nodal me-
tastases [19]. Indeed, our study agreed with others that
there is a significantly higher incidence of pathologic
positivity in the neck then can be expected by exam or
imaging. A recent meta-analysis has demonstrated that
23 % of patients with cN0 neck had positive disease
[19]. However, there does appear to be an association
between periparotid nodes and cervical lymphadenop-
athy. Klussman et al. [20] similarly noted of 36 patients
with intraparotid nodes, 12 had positive cervical nodes
(33 %). This raises the possibility that evidence of peri-
parotid lymph node metastases may be a marker for
more lateral neck nodal disease. In the current study
Table 3 Univariable analysis of overall-, and disease-free survival
and clinicopathological parameters of patients with parotid
gland carcinomas
Univariable testing
Variable Overall survival = Disease-free survival
p-value
pT classification (T1/2 vs. T3/4) <0.0001 <0.0001
pN status (N+ vs. N0) <0.0001 <0.0001
Histopathological grade <0.0001 <0.0001
Perineural invasion <0.0001 <0.0001
Lymphovascular invasion <0.0001 <0.0001
Extracapsular extension <0.0001 <0.0001
Age <60y <0.0001 0.0011
Histological subtype <0.0001 0.0003
Periparotid node involvement <0.0001 <0.0001
Positive Margins 0.37 0.08
pT and pN = pathological T and N classification
Fig. 1 Kaplan-Meier curves for overall survival of 215 patients with parotid gland malignancies stratified by morphology
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lateral neck nodes were more common in those that
had positive periparotid nodes than those that did not.
In addition, almost half of the patients with a positive
periparotid node were staged clinically as being N0.
Thus, a decision for a lateral neck dissection may need
to made at the time of surgery based on identifying a
periparotid node and evaluating for metastases on fro-
zen section analysis.
Multiple studies, including this one, have shown sig-
nificantly worse outcomes with pathologically positive
neck disease [3, 4, 7, 14]. In this cohort of patients, neck
node positivity was a strong predictive factor for recur-
rent disease, in particularly for distant metastatic recur-
rence. In particular, 31 % of patients with nodal
metastases have developed simultaneously distant me-
tastases, primarily to the lungs. Looking at the nodal dis-
ease of all patients that have been included in this study
we observed that subsequently the rate of patients who
died of disease was significantly higher in the neck node
positive group compared to patients with negative nodes
in the neck. Furthermore, the disparity in outcomes may
be underestimated due to a relatively high incidence of pa-
tients with occult cervical metastatic disease not undergo-
ing elective neck dissection.
Lymphovascular invasion was also found to be a
strong predictor of distant metastases and survival. On
multivariable analysis with nodal metastases and grade
included in the model LVI was still found to be a signifi-
cant predictor of survival. One of the limitations was
that the lymphatic and vascular invasion was not
separated in pathology reports to determine whether
one or both are associated with distant metastases and
reduced survival [21, 22]. The high rate of distant metas-
tases in patients with high-grade tumors, nodal metasta-
ses and LVI, points to the need for evaluating systemic
therapies to be used alongside current treatment para-
digms in patients with these high risk features.
As with most series facial nerve paralysis at presentation
in our series was uncommon. While only 12 patients pre-
sented with facial paralysis 36 ultimately required facial
nerve resection. Thus, patients with pre-operatively func-
tioning nerves do need to be made aware of the possibility
of nerve resection when there is evidence of nerve inva-
sion or encasement intra-operatively.
Positive margins were reported in our series in almost
40 % of patients. This included patients that were man-
aged elsewhere and referred in for further management,
as well as cases where tumor was found to be extending
to the margin of the specimen, in regions where the tumor
is intimately related to the facial nerve. On analysis posi-
tive margin status was not a significant predictor of RFS.
Almost all these patients would have received post-
operative adjuvant therapy, thus highlighting the excellent
control rates that can be achieved with adjuvant radiother-
apy in the setting of microscopic positive margins. Lin and
coworkers 26 compared the clinical outcome among 101
patients with salivary gland carcinomas after adjuvant
radiotherapy. Although patients with positive margins had
a shortened disease-free survival their clinical outcome
was equal to those patients with negative margins [23].
Table 5 Multivariable analysis of recurrence-free survival and clinicopathological parameters of patients with parotid carcinomas
Variable Multivariable analysis for recurrence-free survival
p-value Hazard ratio 95 % Confidence Interval
Lymphovascular invasion 0.0482 1.953 1.005 3.794
pN status 0.0076 1.069 1.018 1.122
Perineural invasion 0.0040 2.526 1.345 4.745
Age >60 0.0447 1.749 1.013 3.018
Radiation yes/no 0.6233 0.822 0.375 1.798
Histopathological grade NS
pN = pathological N classification
NS = not significant
Table 4 Multivariable analysis of overall survival and clinicopathological parameters of patients with parotid gland carcinomas
Variable Multivariable analysis for overall survival
p-value Hazard ratio 95 % Confidence Interval
Lymphovascular invasion 0.0020 3.217 1.532 6.755
Histopathological grade 0.0293 3.774 1.312 10.858
pN status 0.0430 1.060 1.002 1.122
Age >60 0.0352 1.990 1.049 3.775
Radiation yes/no 0.0056 0.272 0.106 0.696
pN = pathological N classification
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While the inclusion of the diverse group of pathologies
can be regarded as a limitation to the study we feel that
the study provides an overview of the differences in the
patterns of behaviour. In terms of outcomes, even within
groups there is variability in biology based on tumor
grade and thus tumor grade may provide more prognos-
tic information than the type of parotid cancer.
Conclusions
Our single institution experience has demonstrated that
advanced age, lymph node status, perineural and lym-
phovascular invasion were the strongest predictors of
oncologic outcome. Moreover we have shown that peri-
parotid lymph node involvement has a major impact on
disease-free and overall survival in patients with parotid
carcinomas. The presence of periparotid lymph node in-
volvement should alert the surgeon to the probability of
advanced disease and the need for more aggressive treat-
ment and follow up. Nevertheless, multi-institutional
prospective studies are needed to further address this
question. Currently, there is a phase II RTOG (1008)
trial comparing adjuvant radiation versus chemoradia-
tion in accruing patients with intermediate to high grade
salivary gland carcinomas who have undergone curative
intent surgical resection and are found to have the fol-
lowing risk factors for recurrence: T3-4, or N1-3 disease,
or T1-2 N0 patients with positive or close (≤1 mm)
microscopic margins of resection.
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